HomeGBM • FRA
add
Inovio Pharmaceuticals Inc
Previous close
€4.72
Day range
€4.89 - €4.89
Year range
€4.47 - €12.14
Market cap
144.62M USD
Avg Volume
128.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 100.76K | -55.41% |
Operating expense | 10.21M | -24.52% |
Net income | -32.24M | 9.28% |
Net profit margin | -31.99K | -103.45% |
Earnings per share | -1.19 | 23.72% |
EBITDA | -32.71M | 9.84% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 110.42M | -43.35% |
Total assets | 133.80M | -42.59% |
Total liabilities | 37.06M | -41.79% |
Total equity | 96.74M | — |
Shares outstanding | 25.96M | — |
Price to book | 1.27 | — |
Return on assets | -63.13% | — |
Return on capital | -76.28% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -32.24M | 9.28% |
Cash from operations | -28.21M | 12.70% |
Cash from investing | 9.97M | -81.51% |
Cash from financing | 33.03M | 1,045.85% |
Net change in cash | 14.79M | -39.57% |
Free cash flow | -17.10M | 17.80% |
About
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
Founded
1999
Website
Employees
127
